ViroPedTher SIGNED
Oncolytic viruses for the treatment of pediatric brain tumors: An integrated clinical and lab approach
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ViroPedTher project word cloud
Explore the words cloud of the ViroPedTher project. It provides you a very rough idea of what is the project "ViroPedTher" about.
Project "ViroPedTher" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSIDAD DE NAVARRA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 2˙000˙000 € |
| EC max contribution | 2˙000˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2018-COG |
| Funding Scheme | ERC-COG |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-03-01 to 2024-02-29 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSIDAD DE NAVARRA | ES (PAMPLONA) | coordinator | 2˙000˙000.00 |
Map
Project objective
The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses with the capacity to elicit a therapeutic immune response in those tumors. Our research will use novel and relevant models to accomplish the experimental aims. We have previously worked with Delta-24-RGD (DNX-2401) a replication-competent adenovirus that has been translated to the clinical scenario. In 2017, the first clinical trial phase I with DNX-2401 for newly diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG; a lethal pediatric brain tumor) opened propelled by my team. Preliminary results from the first trials revealed that the intratumoral injection of the virus instigated an initial phase of oncolysis followed by a delayed inflammatory response that ultimately resulted in complete regression in a subset of the patients without associated toxicities. I hypothesized that enhancement of the immune component of the DNX-2401-based therapy will result in the complete regression of the vast majority of pediatric brain tumors. In our specific approach, we propose to understand the immune microenvironment of DIPGs and the response to viral therapy in the context of the trial. Moreover, that knowledge will leverage the design of Delta-24-based adenoviruses to recruit lymphocytes to the tumor with the competence of different type of ligands to activate the tumor infiltrating lymphocytes. I expect that this combinatorial innovative treatment will efficiently challenge the profound and inherent tumor immunosuppression and, in turn, will elicit a robust anti-tumor immune response resulting in the significant improvement of the prognosis and quality of life of patients with pediatric brain tumors. This project has the potential to produce a vertical advance in the field of pediatric oncology.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Naiara MartÃnez-Vélez, Marc Garcia-Moure, Miguel Marigil, Marisol González-Huarriz, Montse Puigdelloses, Jaime Gallego Pérez-Larraya, Marta ZalacaÃn, LucÃa Marrodán, Maider Varela-Guruceaga, Virginia Laspidea, Jose Javier Aristu, Luis Isaac Ramos, Sonia Tejada-SolÃs, Ricardo DÃez-Valle, Chris Jones, Alan Mackay, Jose A. MartÃnez-Climent, Maria Jose GarcÃa-Barchino, Eric Raabe, Michelle The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-10043-0 |
Nature Communications 10/1 | 2020-02-05 |
| 2019 |
Ignacio Iñigo-Marco, Marta M. Alonso Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression published pages: 5086-5088, ISSN: 0021-9738, DOI: 10.1172/jci133115 |
Journal of Clinical Investigation 129/12 | 2020-02-05 |
| 2019 |
Donatas StakiÅ¡aitis, Milda JukneviÄienÄ—, Eligija DamanskienÄ—, Angelija ValanÄiÅ«tÄ—, Ingrida BalnytÄ—, Marta Maria Alonso The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo published pages: 1210, ISSN: 2072-6694, DOI: 10.3390/cancers11081210 |
Cancers 11/8 | 2020-02-05 |
| 2019 |
Naiara Martinez-Velez, Miguel Marigil, Marc GarcÃa-Moure, Marisol Gonzalez-Huarriz, Jose Javier Aristu, Luis-Isaac Ramos-GarcÃa, Sonia Tejada, Ricardo DÃez-Valle, Ana Patiño-GarcÃa, Oren J. Becher, Candelaria Gomez-Manzano, Juan Fueyo, Marta M. Alonso Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-019-0714-6 |
Acta Neuropathologica Communications 7/1 | 2020-02-05 |
| 2019 |
Marc Garcia-Moure, Naiara Martinez-Velez, Marisol Gonzalez-Huarriz, LucÃa Marrodán, Manel Cascallo, Ramón Alemany, Ana Patiño-GarcÃa, Marta M. Alonso The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-019-51014-1 |
Scientific Reports 9/1 | 2020-02-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIROPEDTHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VIROPEDTHER" are provided by the European Opendata Portal: CORDIS opendata.